Please login to the form below

Not currently logged in
Email:
Password:

Greenleaf Health appoints drug and biological products principal

Dr John Jenkins joins the FDA regulatory consulting firm

Washington, US-based Greenleaf Health has appointed Dr John Jenkins as principal for drug and biological products.

Dr Jenkins brings over 25 years of experience from the US Food and Drug Administration (FDA) to the regulatory consulting firm, and is set to oversee its clients' drug development programmes through regulatory submission and post-approval requirements.

Most recently, he served as director of the office of new drugs within the FDA's Center for Drug Evaluation and Research. He previously held several leadership positions at the regulatory body, including director of the office of drug evaluation and director of the division of pulmonary drug products.

Patrick Ronan, chief executive of Greenleaf Health, said: “No one is more qualified than John to provide our clients strategic and technical guidance on FDA's regulatory process for drug and biological product development.

“Our experts at Greenleaf, who have a combined total of more than 200 years of FDA experience, help our clients navigate complex regulatory challenges. John's knowledge and experience in this area are unrivaled, and he makes a great addition to our team.”

20th February 2017

From: Regulatory

Share

Tags

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
McCann Health Medical Communications

We are the medical communications experts within McCann Health. Communicating science to bring meaning and positive change to people’s lives....

Latest intelligence

4 ways to recruit Alzheimer’s disease patients for your clinical trial
What key things do you need to remember to reach patients living with Alzheimer’s disease?...
competitive intelligence
Integrating competitive intelligence into business development, licensing and M&A strategy
The advantages of partnering with a competitive intelligence or knowledge management team...
reaching HCPs during pandemic
Reaching patients and HCPs during the pandemic
COVID-19 has caused unprecedented disruption to drug launches, but some pharma companies avoided costly delays by quickly pivoting to digital channels...

Infographics